Trial Profile
Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Bortezomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Jun 2023 Planned End Date changed from 30 Sep 2022 to 30 Dec 2025.
- 15 Jun 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Dec 2025.
- 26 Aug 2020 Planned initiation date changed from 1 May 2020 to 25 Aug 2020.